Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Bio-Techne (NASDAQ: TECH) just disclosed its Q2 earnings on Wednesday, February 4, 2026 at 06:30 AM. Here's a brief overview ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ...

Bio-Techne Corp. closed 11.77% below its 52-week high of $75.69, which the company achieved on February 7th.

The company's 10-Ks for fiscal year 2025 identify certain factors that could cause the company's actual results to differ ...